<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179283</url>
  </required_header>
  <id_info>
    <org_study_id>Sert-Ven</org_study_id>
    <nct_id>NCT00179283</nct_id>
  </id_info>
  <brief_title>Sertraline vs. Venlafaxine XR</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline&#xD;
      vs. venlafaxine Extended Release in the acute treatment of Major Depression in male and&#xD;
      female outpatient sites that will recruit 15-20 patients each. Subjects will be randomized in&#xD;
      a 1:1 ratio to receive either sertraline or venlafaxine XR based on a computer-generated&#xD;
      randomized list.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline&#xD;
      vs. venlafaxine XR in the acute treatment of Major Depression in male and female outpatient&#xD;
      sites that will recruit 15-20 patients each. Subjects will be randomized in a 1:1 ratio to&#xD;
      receive either sertraline or venlafaxine XR based on a computer-generated randomized list.&#xD;
&#xD;
      The primary objectives of the study are: to assess the comparative safety and tolerability of&#xD;
      sertraline and venlafaxine XR and to assess number and severity of discontinuation symptoms&#xD;
      and time to termination of taper at the end of acute treatment with sertraline vs.&#xD;
      venlafaxine XR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date>April 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ham-D (Hamilton Depression Rating Scale for Depression) 17-item</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression - Severity Scale</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Symptom Scale-Revised (TESS-R)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Symptom Inventory (BSI)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>NEO-5 factor Inventory (NEO-FFI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety Sensitivity Inventory (ASI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood Disorder Questionnaire (MDQ)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ham-A (Hamilton Rating Scale for Anxiety)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arizona Sexual Functioning Inventory (A-SEX)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atypical Features Inventory</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine XR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single or Recurrent Episode of MDD without psychotic features&#xD;
&#xD;
          -  Additional diagnoses will be permitted only if they are identified as secondary&#xD;
             diagnoses&#xD;
&#xD;
          -  18 or above on 17-item Ham-D with item 1 (depressed mood) score of 2 or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or past diagnosis of Bipolar Disorder&#xD;
&#xD;
          -  Any history or current psychotic disorder&#xD;
&#xD;
          -  Current psychotic symptoms, including current delusional depression&#xD;
&#xD;
          -  Current diagnosis of delirium or dementia&#xD;
&#xD;
          -  Alcohol or drug abuse or dependence in last 6 months or currently&#xD;
&#xD;
          -  Schizoid, Schizotypal, or Borderline Personality Disorder&#xD;
&#xD;
          -  Non-response to sertraline at least 150mg for 4 weeks or more, venlafaxine XR at least&#xD;
             225mg for 4 weeks or more, or non-response to 2 antidepressants in the current episode&#xD;
&#xD;
          -  Use of any antidepressant within 2 weeks of baseline (4 weeks for fluoxetine)&#xD;
&#xD;
          -  Use of herbal and/or homeopathic remedies concomitantly or within 2 weeks of baseline&#xD;
             excluding vitamins and mineral supplements&#xD;
&#xD;
          -  Use within 1 week of baseline or concomitant use of any psychotropics with the&#xD;
             exception zolpidem or zopiclone PRN for sleep&#xD;
&#xD;
          -  Use within 4 weeks of baseline of benzodiazepines taken on a regular, daily basis (PRN&#xD;
             use is acceptable as long as none in week leading up to randomization)&#xD;
&#xD;
          -  Score of 3 or 4 on the suicide item, item 3 of the Ham-D scale at screen or baseline&#xD;
             visit&#xD;
&#xD;
          -  Participation in any other studies concomitantly or within 90 days prior to entry into&#xD;
             this study&#xD;
&#xD;
          -  Treatment with monoamine oxidase inhibitors within 14 days of baseline&#xD;
&#xD;
          -  Treatment of electroconvulsive therapy within 30 days of baseline&#xD;
&#xD;
          -  Previous history or intolerance or hypersensitivity and/or venlafaxine XR&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the study protocol&#xD;
&#xD;
          -  Presence of serious and/or unstable medical condition&#xD;
&#xD;
          -  Abnormal laboratory results&#xD;
&#xD;
          -  Positive pregnancy test and/or nursing women or fertile women not practicing an&#xD;
             effective method of birth control&#xD;
&#xD;
          -  History seizure disorder-excluding febrile seizures of childhood&#xD;
&#xD;
          -  Any other condition which in the investigator's judgement might increase the risk to&#xD;
             the subject or decrease the chance of obtaining satisfactory data&#xD;
&#xD;
          -  Mental condition rendering the subject unable to understand the procedures&#xD;
&#xD;
          -  Unable and/or unlikely to comprehend and/or follow the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard C Shelton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Richard C. Shelton</investigator_full_name>
    <investigator_title>Director of Mood Disorders Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

